TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11285325

Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Linola oil
Number of subjects: 40
Study: 9292585

Group type: EXPERIMENTAL
Intervention: recombinant gp160 (r-gp160) immunization
Number of subjects: 76
Study: 8308770

Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drug (NSAID) therapy
Number of subjects: 26
Study: 2962333

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide 0.05 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium bromide 0.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.25 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salbutamol 2.5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study: 29776961

Group type: EXPERIMENTAL
Intervention: MR-proADM
Number of subjects: 1122
Study: 27002215

Group type: EXPERIMENTAL
Intervention: C-SASS (SASS delivered by school counselors)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: P-SASS (SASS delivered by psychologists)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (Skills for Life - SFL)
Number of subjects: 138
Study: 25902142

Group type: EXPERIMENTAL
Intervention: Incentive-to-fake condition
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 65
Study: 23562005

Group type: EXPERIMENTAL
Intervention: Sarcosine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 40
Study: 20399986

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/d plus telmisartan 80 mg/d (RT group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg/d plus irbesartan 300 mg/d (RI group)
Number of subjects: 151

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg/d plus olmesartan 20 mg/d (RO group)
Number of subjects: 151
Study: 17884266

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment in patients with schizophrenia
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessment using the Schizophrenia Quality of Life Scale
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neuropsychological functioning
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Empathy in QOL
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Social knowledge and memory
Number of subjects: 53
Study: 15730920

Group type: EXPERIMENTAL
Intervention: Enteral nutritional support
Number of subjects: 40

Group type: COMPARATOR
Intervention: Parenteral nutritional support
Number of subjects: 40
Study: 14527091

Group type: EXPERIMENTAL
Intervention: Low-fat vegetarian diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-fat non-vegetarian diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-fat vegetarian diet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-fat non-vegetarian diet
Number of subjects: 18
Study: 11320434

Group type: EXPERIMENTAL
Intervention: Rarely Missed Index (RMI) calculated from the Logical Memory Delayed Recognition (LMDR) items
Number of subjects: 137

Group type: COMPARATOR
Intervention: Logical Memory Delayed Recognition (LMDR) subtest
Number of subjects: 137
Study: 8844448

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily for 9 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1384438

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Serenoa Repens
Number of subjects: 45
Study: 6406586

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (acute phase)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (sustained phase)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitroglycerin (acute therapy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitroglycerin (sustained therapy)
Number of subjects: 10
Study: 31201876

Group type: EXPERIMENTAL
Intervention: Immediate-release morphine as needed
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Titration of morphine
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Titrate baseline oxycodone
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Stepwise switch to morphine
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Add morphine on baseline oxycodone
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Add morphine on baseline fentanyl
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 536
Study: 29385358

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 363

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 363
Study: 26774515

Group type: EXPERIMENTAL
Intervention: Socially anxious participants (SAD and high socially anxious students)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonanxious participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall gaze patterns
Number of subjects: 0
Study: 24111929

Group type: EXPERIMENTAL
Intervention: Breathing oxygen (FIO2 28% and 35%)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Breathing oxygen (FIO2 35%)
Number of subjects: 29
Study: 22580407

Group type: EXPERIMENTAL
Intervention: Scenario with greater utility for positive sequences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scenario with greater utility for negative sequences
Number of subjects: 0
Study: 20111849

Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin‐A (Dysport 500‐1000U)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 18048467

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 36
Study: 15692475

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (200 mg once weekly, 5 40‐mg tablets)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 43
Study: 11792411

Group type: EXPERIMENTAL
Intervention: FISH panel testing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: M-FISH
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard cytogenetics
Number of subjects: 32

Group type: COMPARATOR
Intervention: FISH panel test
Number of subjects: 32
Study: 10649166

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (1 g/kg body weight) for 2 consecutive days each month until 36 weeks' gestation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 2 consecutive days each month until 36 weeks' gestation
Number of subjects: 16
Study: 9153784

Group type: EXPERIMENTAL
Intervention: Methanol administered orally at a dose of 10 mg/kg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Methanol administered intravenously at a dose of 10 mg/kg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Comparison of methanol elimination kinetics between alcoholics and non-alcoholics
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intraindividual variation in methanol elimination
Number of subjects: 5
Study: 8475628

Group type: EXPERIMENTAL
Intervention: Hypokinesia with daily fluid and salt supplements (water 26 ml/kg body weight and sodium chloride 0.16 g/kg body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hypokinesia (pure)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Long-distance running (control group)
Number of subjects: 30
Study: 3895186

Group type: EXPERIMENTAL
Intervention: Carotenoid treatment (100 mg daily of betacarotene and canthaxanthine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxychloroquine treatment (200 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 29244885

Group type: EXPERIMENTAL
Intervention: Dual-curing resin cement (RelyX ARC, 3M ESPE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Self-adhesive resin cement (RelyX U200, 3M ESPE)
Number of subjects: 80
Study: 27614854

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24622068

Group type: EXPERIMENTAL
Intervention: 3D reconstruction of peripancreatic vessels
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 89
Study: 23420010

Group type: EXPERIMENTAL
Intervention: Study group (culture results reported as 'mixed growth')
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (culture results reported as usual)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 20146387

Group type: EXPERIMENTAL
Intervention: High frequency chest wall oscillation (vest)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutter device (FD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postural drainage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 17822705

Group type: EXPERIMENTAL
Intervention: Empowerment group education programme
Number of subjects: 28

Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 28
Study: 16884976

Group type: EXPERIMENTAL
Intervention: Desflurane (volatile anesthetic)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Propofol (intravenous anesthetic)
Number of subjects: 112
Study: 12972520

Group type: EXPERIMENTAL
Intervention: Exisulind 125 mg orally bid in combination with capecitabine 2,000 mg/m2 for 14 days in 21-day cycles
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Exisulind 125 mg orally bid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 35
Study: 10623702

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin
Number of subjects: 522

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 522
Study: 8840343

Group type: EXPERIMENTAL
Intervention: Amitriptyline 30 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flupentixole 1.5 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clotiazepam 15 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meta-analysis of all agents
Number of subjects: 30
Study: 1634784

Group type: COMPARATOR
Intervention: Diazepam (0.1 mg/kg) followed by placebo (0.5 mg/kg as bolus and 0.5 mg/kg/hour infusion)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Diazepam (0.1 mg/kg) followed by ketamine (0.5 mg/kg as bolus and 0.5 mg/kg/hour infusion)
Number of subjects: 100
Study: 30424786

Group type: EXPERIMENTAL
Intervention: GSK1120360A (prolyl hydroxylase inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daprodustat (clinical prolyl hydroxylase inhibitor)
Number of subjects: 0
Study: 27548026

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 113

Group type: COMPARATOR
Intervention: Healthy Eating diet
Number of subjects: 113
Study: 25448495

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) administered 1 hour before surgery
Number of subjects: 60
Study: 22879399

Group type: EXPERIMENTAL
Intervention: Early weightbearing (EWB) group (40 ankles)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Delayed weightbearing (DWB) group (41 ankles)
Number of subjects: 81
Study: 19844694

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg fish oil (FO) 1 day before LPS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg fish oil (FO) 1 day before LPS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg fish oil (FO) 2 hours before LPS
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group from Pluess et al. trial
Number of subjects: 3
Study: 18676544

Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Number of subjects: 104

Group type: COMPARATOR
Intervention: No breakfast (Control)
Number of subjects: 104
Study: 15878930

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: TPOAb (+) women
Number of subjects: 72

Group type: COMPARATOR
Intervention: TPOAb (−) women
Number of subjects: 72
Study: 14704377

Group type: EXPERIMENTAL
Intervention: Treatment group (case managers with risk and benefit information)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (case managers with only patient assessments)
Number of subjects: 24
Study: 10546917

Group type: EXPERIMENTAL
Intervention: LI160 (900 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8914412

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (fluticasone propionate; Flunase) and antiallergic medicine (azelastin) administered 4 weeks before pollen season (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Antiallergic medicine (azelastin) administered at the same time as Group A, with topical corticosteroid given after symptoms appeared (Group B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (fluticasone propionate; Flunase) in Group A
Number of subjects: 25
Study: 1854375

Group type: EXPERIMENTAL
Intervention: Alcohol (0.25 g/kg‐1 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6587183

Group type: EXPERIMENTAL
Intervention: Combination of surgery and adjuvant chemotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Repeated or bilateral thoracotomies
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Wedge excision
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dn bloc resection of pericardium, chest wall, and diaphragm
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Tumor-free interval greater than 8 months
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Chest X-ray
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 22
Study: 30932047

Group type: EXPERIMENTAL
Intervention: High-risk genetic test result for obesity
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Protected genetic test result for obesity
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Perceived genetic risk
Number of subjects: 223
Study: 29504985

Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 40
Study: 26920949

Group type: EXPERIMENTAL
Intervention: Acotiamide (300 mg/day) and rabeprazole (10 mg/day) combination therapy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Acotiamide (300 mg/day)
Number of subjects: 81
Study: 24554392

Group type: EXPERIMENTAL
Intervention: Telemedicine-based CPAP follow-up (study 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Videoconference CPAP training (study 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Face-to-face CPAP training (study 2)
Number of subjects: 90
Study: 22721612

Group type: EXPERIMENTAL
Intervention: Intravenous glutamate infusion
Number of subjects: 861

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 861
Study: 20585296

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate drink
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 18
Study: 16484110

Group type: EXPERIMENTAL
Intervention: False memories that imported perceived features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived details misattributed to false memories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False memories of imagined objects
Number of subjects: 0
Study: 14586388

Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Smoked methamphetamine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous methamphetamine
Number of subjects: 8
Study: 11156742

Group type: EXPERIMENTAL
Intervention: Living food (LF) diet
Number of subjects: 0
Study: 8785132

Group type: EXPERIMENTAL
Intervention: Induced hypotension using sodium nitroprusside, trimetaphan camsylate, or additional isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induced hypotension using trimetaphan camsylate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induced hypotension (all techniques)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Induced hypotension for middle ear surgery
Number of subjects: 30
Study: 1388181

Group type: EXPERIMENTAL
Intervention: Dissection present
Number of subjects: 693

Group type: COMPARATOR
Intervention: No dissection
Number of subjects: 693
Study: 2856779

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 0
Study: 30569083

Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg daily for 12 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 29286928

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 240
Study: 25459391

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m² plus cisplatin (70mg/m²) or carboplatin (AUC=5)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m² plus trastuzumab (8mg/kg loading dose, then 6 mg/kg every 21 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Trastuzumab with cisplatin
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Trastuzumab with carboplatin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (Arm A vs Arm B)
Number of subjects: 61
Study: 23489705

Group type: EXPERIMENTAL
Intervention: Pidotimod 400 mg, administered orally once a day for 90 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21076842

Group type: EXPERIMENTAL
Intervention: Postexercise muscle ischemia (PEMI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No PEMI (control trial)
Number of subjects: 9
Study: 19189986

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg kg(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 30
Study: 17076456

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture plus standard emergency medical care
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard emergency medical care
Number of subjects: 87

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 87
Study: 15639698

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream QD for 12 weeks
Number of subjects: 847

Group type: COMPARATOR
Intervention: Vehicle cream QD for 12 weeks
Number of subjects: 847
Study: 12370877

Group type: EXPERIMENTAL
Intervention: Ischemic compression (P1, pain threshold; P2, averaged pain threshold and tolerance) with durations (T1, 30s; T2, 60s; T3, 90s)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Therapeutic combinations (B1: hot pack plus active ROM; B2: B1 plus ischemic compression; B3: B2 plus TENS; B4: B1 plus stretch with spray; B5: B4 plus TENS; B6: B1 plus interferential current and myofascial release)
Number of subjects: 119
Study: 9440585

Group type: EXPERIMENTAL
Intervention: Prophylactic heparin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Heparin bonding
Number of subjects: 14
Study: 8119037

Group type: EXPERIMENTAL
Intervention: Autologous shed blood
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pall RC100 filter
Number of subjects: 128
Study: 2504897

Group type: EXPERIMENTAL
Intervention: 14-day OKT3
Number of subjects: 68

Group type: COMPARATOR
Intervention: 10-day OKT3
Number of subjects: 68
Study: 1252342

Group type: EXPERIMENTAL
Intervention: High temperature crude coal tar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low temperature crude coal tar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard refined tar
Number of subjects: 0
Study: 31777236

Group type: EXPERIMENTAL
Intervention: Yinqi Guiyuan needling (punctured with filiform needles for 30 min, three times per week for 4 weeks)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Estazolam (oral tablets once a day for 4 weeks)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Yinqi Guiyuan needling
Number of subjects: 79

Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 79
Study: 27130075

Group type: EXPERIMENTAL
Intervention: Insulin treatment regimens (biphasic, aspart, detemir) in addition to metformin or placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Weight gain during the first 3 months of the trial and subsequent dose of insulin
Number of subjects: 412
Study: 25468411

Group type: EXPERIMENTAL
Intervention: Capsaicin capsules
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study: 23308016

Group type: EXPERIMENTAL
Intervention: Losartan, 100 mg (n=77)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (n=76)
Number of subjects: 153
Study: 21228732

Group type: EXPERIMENTAL
Intervention: Enteral supplementation of prebiotics (SC GOS/LC FOS/AOS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study: 18097505

Group type: EXPERIMENTAL
Intervention: G. lucidum extract (6 mg once a day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 17038636

Group type: EXPERIMENTAL
Intervention: AHA step 1 diet plus simvastatin (40 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: AHA step 1 diet alone
Number of subjects: 70
Study: 12527538

Group type: EXPERIMENTAL
Intervention: MED+DBT
Number of subjects: 34

Group type: COMPARATOR
Intervention: MED
Number of subjects: 34
Study: 11286606

Group type: EXPERIMENTAL
Intervention: Test brand (sugar-coated chloroquine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control chloroquine phosphate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 9210109

Group type: EXPERIMENTAL
Intervention: Computer reading treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Computer stimulation
Number of subjects: 55

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 55
Study: 7965443

Group type: EXPERIMENTAL
Intervention: Affected (hemiplegic) side
Number of subjects: 19

Group type: COMPARATOR
Intervention: Unaffected (control) side
Number of subjects: 19
Study: 3277904

Group type: EXPERIMENTAL
Intervention: Intermittent chlorambucil once a month
Number of subjects: 59

Group type: COMPARATOR
Intervention: No treatment (observation)
Number of subjects: 59
Study: 30466334

Group type: EXPERIMENTAL
Intervention: Self-paced exercise (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Prescribed moderate-intensity exercise (n = 29)
Number of subjects: 59